Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Blood

• Publication date

  2011-11-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2011-02-339432PMID 21911831PMCID PMC3217403
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.

  2011cited by this paper
• New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network

  2010cited by this paper
• Principles of cancer therapy: oncogene and non-oncogene addiction.

  2009cited by this paper
• In vitro and In vivo Radiosensitization with AZD6244 (ARRY-142886), an Inhibitor of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase 1/2 Kinase

  2009cited by this paper
• Targeting slow‐proliferating ovarian cancer cells

  2009cited by this paper
• KLF4 is a FOXO target gene that suppresses B cell proliferation.

  2008cited by this paper
• Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.

  2008cited by this paper
• AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

  2008cited by this paper
• Regulation of DNA repair throughout the cell cycle

  2008cited by this paper
• Flow cytometry-based cell cycle measurement of mouse hematopoietic stem and progenitor cells.

  2008cited by this paper
• Expanded Roles for Chk1 in Genome Maintenance*

  2008cited by this paper
• Switching from Repression to Activation: MicroRNAs Can Up-Regulate Translation

  2007cited by this paper
• ERK1/2‐dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl‐1 and Bcl‐xL

  2007cited by this paper
• Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

  2007cited by this paper
• Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

  2007cited by this paper
• Pharmacological Abrogation of S-Phase Checkpoint Enhances the Anti-Tumor Activity of Gemcitabine In Vivo

  2007cited by this paper
• Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation.

  2007cited by this paper
• Hyperactive Ras in developmental disorders and cancer

  2007cited by this paper
• Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response.

  2007cited by this paper
• Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.

  2007cited by this paper
• The ATR pathway: fine-tuning the fork.

  2007cited by this paper
• DNA damage checkpoints: from initiation to recovery or adaptation.

  2007cited by this paper
• Specific Role of Chk1 Phosphorylations in Cell Survival and Checkpoint Activation

  2007cited by this paper
• MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.

  2007cited by this paper
• Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.

  2007cited by this paper
• Ras Triggers Ataxia-telangiectasia-mutated and Rad-3-related Activation and Apoptosis through Sustained Mitogenic Signaling*

  2006cited by this paper
• An intrinsic cell cycle checkpoint pathway mediated by MEK and ERK in Drosophila.

  2006cited by this paper
• DNA nucleotide excision repair-dependent signaling to checkpoint activation

  2006cited by this paper
• DNA damage checkpoints in mammals.

  2006cited by this paper
• Isolation and characterization of side population cells.

  2005cited by this paper
• Inhibition of Human Chk1 Causes Increased Initiation of DNA Replication, Phosphorylation of ATR Targets, and DNA Breakage

  2005cited by this paper
• The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair

  2005cited by this paper
• Cell-cycle checkpoints and cancer

  2004cited by this paper
• The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice.

  2004cited by this paper
• The MAP kinase pathway is required for entry into mitosis and cell survival

  2004cited by this paper
• Chk1 and Chk2 kinases in checkpoint control and cancer.

  2003cited by this paper
• Regulatory Interactions between the Checkpoint Kinase Chk1 and the Proteins of the DNA-dependent Protein Kinase Complex*

  2003cited by this paper
• CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).

  2003cited by this paper
• Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.

  2002cited by this paper
• Multiple myeloma: evolving genetic events and host interactions

  2002cited by this paper
• MAPK dependence of DNA damage repair: ionizing radiation and the induction of expression of the DNA repair genes XRCC1 and ERCC1 in DU145 human prostate carcinoma cells in a MEK1/2 dependent fashion

  2001cited by this paper
• Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.

  2001cited by this paper
• Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma.

  1999cited by this paper
• Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans.

  1999cited by this paper
• Orderly process of sequential cytokine stimulation is required for activation and maximal proliferation of primitive human bone marrow CD34+ hematopoietic progenitor cells residing in G0.

  1997cited by this paper
• Orderly Process of Sequential Cytokine Stimulation Is Required for Activation and Maximal Proliferation of Primitive Human Bone Marrow CD34+ Hematopoietic Progenitor Cells Residing in G0

  1997cited by this paper
• Identification of resting cells by dual-parameter flow cytometry of statin expression and DNA content.

  1995cited by this paper
• Confluence‐dependent resistance in human colon cancer cells: Role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells

  1992cited by this paper
• Creative blocks: cell-cycle checkpoints and feedback controls

  1992cited by this paper
• Rapid disappearance of statin, a nonproliferating and senescent cell- specific protein, upon reentering the process of cell cycling

  1985cited by this paper
• The growth fraction of human myeloma cells.

  1981cited by this paper

• Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3‐dependent mechanism in vitro and in vivo

  2024cites this paper
• Human aneuploid cells depend on the RAF/MEK/ERK pathway for overcoming increased DNA damage

  2023cites this paper
• The important regulatory roles of circRNA-encoded proteins or peptides in cancer pathogenesis (Review)

  2023cites this paper
• Nanog mediated by FAO/ACLY signaling induces cellular dormancy in colorectal cancer cells

  2022cites this paper
• Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted Therapy

  2022cites this paper
• Advances in therapeutic agents targeting quiescent cancer cells

  2022cites this paper
• Chk1 inhibitor-induced DNA damage increases BFL1 and decreases BIM but does not protect human cancer cell lines from Chk1 inhibitor-induced apoptosis.

  2021cites this paper
• CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment

  2021cites this paper
• CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma

  2021cites this paper
• Towards a Framework for Better Understanding of Quiescent Cancer Cells

  2021influential citation
• Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells

  2020cites this paper
• ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias.

  2020cites this paper
• CD138- multiple myeloma cells express high level of CHK1 which correlated to overall survival in MM patient

  2020cites this paper
• Probing the mechanism for hydrogel-based stasis induction in human pluripotent stem cells: is the chemical functionality of the hydrogel important?

  2019cites this paper
• Kinome expression profiling to target new therapeutic avenues in multiple myeloma

  2019cites this paper
• Checkpoint kinase inhibitor AZD7762 enhance cisplatin-induced apoptosis in osteosarcoma cells

  2019cites this paper
• Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer

  2019cites this paper
• Cancer Cell Glycocalyx and Its Significance in Cancer Progression

  2018cites this paper
• Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma

  2018cites this paper
• Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

  2018cites this paper
• Targeting CHK1 for Cancer Therapy: Rationale, Progress and Prospects

  2018cites this paper
• ATR/CHK1 inhibitors and cancer therapy.

  2017cites this paper
• YM155 exerts potent cytotoxic activity against quiescent (G0/G1) multiple myeloma and bortezomib resistant cells via inhibition of survivin and Mcl-1

  2017cites this paper
• DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy.

  2017cites this paper
• Mucin-Inspired Thermoresponsive Synthetic Hydrogels Induce Stasis in Human Pluripotent Stem Cells and Human Embryos

  2016cites this paper
• Kinase inhibitors as potential agents in the treatment of multiple myeloma

  2016cites this paper
• DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7.

  2016cites this paper
• mTORC1 and DNA‐PKcs as novel molecular determinants of sensitivity to Chk1 inhibition

  2016cites this paper
• Identification potential biomarkers and therapeutic agents in multiple myeloma based on bioinformatics analysis.

  2016cites this paper
• A Phase II Trial of AZD 6244 ( Selumetinib , ARRY-142886 ) , an Oral MEK 1 / 2 Inhibitor , in Relapsed / Refractory Multiple Myeloma

  2015cites this paper
• Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.

  2015cites this paper
• A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

  2015cites this paper
• Advances in the molecular functions of syndecan-1 (SDC1/CD138) in the pathogenesis of malignancies.

  2015cites this paper
• Circumvention of Mcl-1-Dependent Drug Resistance by Simultaneous Chk1 and MEK1/2 Inhibition in Human Multiple Myeloma Cells

  2014cites this paper
• Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes.

  2014cites this paper
• CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy.

  2014cites this paper
• MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner.

  2013cites this paper
• The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair

  2013cites this paper
• Targeting syndecans: a promising strategy for the treatment of cancer

  2013cites this paper
• DNA repair pathways in human multiple myeloma

  2013cites this paper
• Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy.

  2013cites this paper
• Targeting the Cell Cycle for Cancer Treatment and Neuroprotection

  2013cites this paper
• Chemical Therapeutics The Novel Chk 1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair

  2013cites this paper
• Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma

  2012cites this paper
• Enhancing CHK1 inhibitor lethality in glioblastoma

  2012cites this paper
• The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models

  2012cites this paper
• Resveratrol Sensitizes Acute Myelogenous Leukemia Cells to Histone Deacetylase Inhibitors through Reactive Oxygen Species-Mediated Activation of the Extrinsic Apoptotic Pathway

  2012influential citation